Table 5. Summary of clinical benefit rate (SD/PR/CR, 16 weeks).
| Buparlisib (BKM120) | Dovitinib (TKI258) | Binimetinib (MEK162) | Encorafenib (LGX818) | Sonidegib (LDE225) | BGJ398 | Ceritinib (LDK378) | Ribociclib (LEE011) | Total | |
|---|---|---|---|---|---|---|---|---|---|
| Dosed patients, n | 146 | 80 | 110 | 12 | 10 | 82a | 47 | 106 | 593a |
| Clinical benefit, n (%) | 22 (15.1) | 11 (13.8) | 25 (22.7) | 3 (25.0) | 0 | 12 (14.6) | 9 (19.1) | 19 (17.9) | 101 (17.0) |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease.
a Excluded treatment-induced osteomalacia–only patients.